Osteosarcoma is the most common malignant primary bone tumor in childhood. Despite multiagent chemotherapy and aggressive surgical resection, 30% of patients with localized disease and 80% of ...

Lead author Dr. Darrell Green, of UEA's Norwich Medical School, said, "Since the 1970s, osteosarcoma has been treated using untargeted chemotherapy and surgery, which sometimes results in limb ...

Osteosarcoma is a type of bone cancer that originates in the cells that form an individual's bones. In rare cases, it may ...

Osteosarcoma is the most common bone malignancy in children. Advances in the treatment of this malignancy have improved survival rates for patients. Incorporating health-related quality of life ...

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today provided a corporate update to the ...

for treating adults with relapsed or refractory osteosarcoma after a minimum of two lines of previous therapy. "EC approves GSK’s Jemperli-chemo combo for endometrial cancer" was originally created ...

For patients with relapsed or refractory osteosarcoma, there is an urgent unmet medical need with no approved treatment options once the cancer returns a second time, and chemotherapy provides limited ...

“For patients with relapsed or refractory osteosarcoma, there is an urgent unmet medical need with no approved treatment options once the cancer returns a second time, and chemotherapy provides ...

OS Therapies (NYSE:OSTX) is up ~65% in premarket trading Wednesday after releasing phase 2b data on OST-HER2 for prevention of recurrent, fully resected, lung metastatic osteosarcoma. Results ...

Currently, the standard approach for treatment of patients with osteosarcoma consists of 10 weeks of preoperative chemotherapy, surgical resection and 20 weeks of postoperative chemotherapy.